ENABLE-2 programmes
ENABLE-2 is currently supporting five promising programmes in the pursuit of new antibiotics: From Justus Liebig University Giessen, The Ineos Oxford Institute at the University of Oxford, Leiden University & Queen’s University Belfast, Uppsala University and QureTech Bio.
Programme BamA Inhibitors
Novel antibiotics that hit a new target against Gram-negative bacteria.
Resident at
Contact
Till F. Schäberle, PhD, Principal Investigator
Justus Liebig University Giessen
Till.F.Schaeberle@agrar.uni-giessen.de
Programme Broad-spectrum MBL inhibitors
A new class of broad spectrum metallo-b-lactamase inhibitors that restore activity of carbapenems in MDR Gram-negative Enterobacterales
Resident at
Contact
Alistair Farley, Dr, Scientific Lead
Ineos Oxford Institute at the University of Oxford
Alistair.farley@chem.ox.ac.uk
Christopher Schofield
Professor of Chemistry, University of Oxford
Director of Chemistry, Ineos Oxford Institute at the University of Oxford
Christopher.schofield@chem.ox.ac.uk
Programme GmPcides
A new class of antibacterial compounds against gram-positive bacteria & a well-developed chemistry platform to improve these new compounds.
Resident at
Contact
Fredrik Almqvist, Research Director
QureTech Bio AB
Fredrik.Almqvist@umu.se
Helén Fält, CEO
QureTech Bio AB
Helen.Falt@quretech.com
Programme JEDI
A novel target with no preexisting resistance and a new compound class showing very good efficacy in animal models.
Resident at
Contact
Diarmaid Hughes, Professor
Uppsala University
Diarmaid.Hughes@imbim.uu.se
Anders Karlén, Professor
Uppsala University
Anders.Karlen@ilk.uu.se
Programme Ornicidine
A novel class of anti-bacterial agents active against multi drug-resistant Gram-negative bacteria.
Resident at
Contact
Nathaniel Martin, Professor
Leiden University
n.i.martin@biology.leidenuniv.nl
Stephen Cochrane, Dr.
Queen’s University Belfast
s.cochrane@qub.ac.uk
Learn more
Contact ENABLE-2
Marie Olliver, PhD, Alliance Manager
Uppsala University
Marie.Olliver@ilk.uu.se
ENABLE-2 funders
ENABLE-2 is supported by the Swedish Research Council, the National Research Programme on Antibiotic Resistance and Sweden's innovation agency Vinnova.
